Skip to main content

Drug Interactions between Scot-Tussin Original (old formulation) and Urapine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

phenylephrine methylene blue

Applies to: Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate) and Urapine (hyoscyamine / methenamine / methylene blue / phenyl salicylate)

Using methylene blue together with phenylephrine is not recommended. Combining these medications can cause dangerously high blood pressure and even death. You may use phenylephrine only after you have been off methylene blue for at least 14 days. You should seek immediate medical attention if you experience sudden and severe headache, blurred vision, confusion, seizures, chest pain, nausea or vomiting, sudden numbness or weakness (especially on one side of the body), speech difficulties, fever, sweating, lightheadedness, and/or fainting during treatment with methylene blue, as these may be signs and symptoms of excessively high blood pressure. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

phenylephrine caffeine

Applies to: Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate) and Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate)

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res 1 (1979): 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656
  3. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  4. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  5. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  6. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  7. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
View all 7 references
Moderate

phenylephrine hyoscyamine

Applies to: Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate) and Urapine (hyoscyamine / methenamine / methylene blue / phenyl salicylate)

Hyoscyamine may increase the effects of phenylephrine on your blood pressure and heart rate. Before receiving these medications, you should let your doctor know if you have high blood pressure or heart disease. You may not be able to use one or both of these medications, or you may need closer monitoring by your doctor in order to use these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

hyoscyamine pheniramine

Applies to: Urapine (hyoscyamine / methenamine / methylene blue / phenyl salicylate) and Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate)

Using hyoscyamine together with pheniramine may increase side effects such as drowsiness, blurred vision, dry mouth, heat intolerance, flushing, decreased sweating, difficulty urinating, abdominal cramping, constipation, irregular heartbeat, confusion, and memory problems. Side effects may be more likely to occur in the elderly or those with a debilitating condition. You should avoid or limit the use of alcohol while being treated with these medications. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

sodium salicylate phenyl salicylate

Applies to: Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate) and Urapine (hyoscyamine / methenamine / methylene blue / phenyl salicylate)

Using sodium salicylate together with phenyl salicylate is generally not recommended. Combining these medications may increase the risk of side effects in the gastrointestinal tract such as inflammation, pain, bleeding, and ulceration. Bruising and other bleeding complications may also occur. You should take these medications with food to lessen gastrointestinal side effects. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as dizziness; lightheadedness; red or black, tarry stools; coughing up or vomiting fresh or dried blood that looks like coffee grounds; severe headache; and weakness. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

methenamine sodium citrate

Applies to: Urapine (hyoscyamine / methenamine / methylene blue / phenyl salicylate) and Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate)

Sodium citrate may reduce the effectiveness of methenamine in treating your condition. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

sodium salicylate sodium citrate

Applies to: Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate) and Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate)

Using sodium citrate together with sodium salicylate may decrease the effects of sodium salicylate. Contact your doctor if your condition changes. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

phenyl salicylate sodium citrate

Applies to: Urapine (hyoscyamine / methenamine / methylene blue / phenyl salicylate) and Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate)

Using sodium citrate together with phenyl salicylate may decrease the effects of phenyl salicylate. Contact your doctor if your condition changes. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

pheniramine food

Applies to: Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate)

Alcohol can increase the nervous system side effects of pheniramine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with pheniramine. Do not use more than the recommended dose of pheniramine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.

Switch to professional interaction data

Moderate

hyoscyamine food

Applies to: Urapine (hyoscyamine / methenamine / methylene blue / phenyl salicylate)

Ask your doctor before using hyoscyamine together with ethanol. Use alcohol cautiously. Alcohol may increase drowsiness and dizziness while you are taking hyoscyamine. You should be warned not to exceed recommended dosages and to avoid activities requiring mental alertness. If your doctor prescribes these medications together, you may need a dose adjustment to safely take this combination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

phenylephrine food

Applies to: Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate)

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res 1 (1979): 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656
  3. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  4. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  5. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  6. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  7. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
View all 7 references
Minor

caffeine food

Applies to: Scot-Tussin Original (old formulation) (caffeine / pheniramine / phenylephrine / sodium citrate / sodium salicylate)

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Nonsteroidal anti-inflammatories

Therapeutic duplication

The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category:

  • Scot-Tussin Original (old formulation) (caffeine/pheniramine/phenylephrine/sodium citrate/sodium salicylate)
  • Urapine (hyoscyamine/methenamine/methylene blue/phenyl salicylate)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.